改进慢性肾脏病特异性患者报告的生活质量影响量表
该研究在485例不同治疗阶段(非透析3-5期、透析、移植后)的CKD患者中,比较了新开发的CKD-QOL影响量表与KDQOL-36及通用SF-12的效度。结果显示CKD-QOL在多项临床效度检验中表现优于KDQOL-36,且计算机自适应测试(CAT)比静态表单更高效。
要点
- CKD-QOL在区分临床状态变化上效度约为KDQOL-36的两倍。
- KDQOL-36和CKD-QOL的区分能力普遍优于通用SF-12。
- CAT版本与静态版本效果相似,但CAT更高效。
核心结论
- 新CKD-QOL影响量表在多项效度检验中整体优于KDQOL-36。
- CAT调查比静态调查更高效。
研究设计与样本
- 纳入485例CKD患者,包括非透析3-5期、透析和移植后组。
- 患者在基线及3个月时完成CKD-QOL、KDQOL-36和SF-12问卷。
- CKD-QOL通过六项静态表单和包含3-6项的CAT生成单一影响评分。
主要发现
- KDQOL-36和CKD-QOL的区分能力普遍优于SF-12v2。
- 在CKD特异性检验中,CKD-QOL解释的方差约为KDQOL-36的两倍。
- 两项相对效度(RV)检验证实CKD-QOL优于参照的KDQOL负担子量表。
- 静态与CAT版本的CKD-QOL结果相似。
- SF-12生理评分和KDQOL-36症状评分随合并症数量增加而恶化。
关键数值与推荐
- 效度比较采用方差分析和相对效度(RV),参照KDQOL-36负担子量表。
- 临床状态检验包括4项CKD特异性测试及临床医生对变化的评估。
临床怎么用
- CKD-QOL可作为评估CKD患者生活质量影响的更优工具。
- CAT形式可能提高评估效率,适合临床常规使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patient-reported outcome measures that are more practical and clinically useful are needed for patients with CKD. We compared a new CKD-specific quality-of-life impact scale (CKD-QOL) with currently used measures. METHODS: Patients (n=485) in different treatment groups (nondialysis stages 3-5, on dialysis, or post-transplant) completed the kidney-specific CKD-QOL and Kidney Disease Quality of Life-36 (KDQOL-36) forms and the generic SF-12 Health Survey at baseline and 3 months. New items summarizing quality of life (QOL) impact attributed to CKD across six QOL domains yielded single impact scores from a six-item static (fixed-length) form and from computerized adaptive tests (CATs) with three to six items. Validity tests compared the CKD-QOL, KDQOL-36 (Burden, Effects, and Symptoms/Problems subscales), and generic SF-12 measures across groups in four tests of clinical status and clinician assessment of change (CKD-specific tests), and number of comorbidities. ANOVA was used to test for group mean differences, variances in each measure explained by groups, and relative validity (RV) in comparison with the referent KDQOL-36 Burden subscale. RESULTS: KDQOL-36 and CKD-QOL measures generally discriminated better than generic SF-12v2 measures. The pattern of variances across CKD-specific tests comparing validity favored CKD-QOL two-fold over KDQOL-36. Two RV test results confirmed CKD-QOL improvements over the referent KDQOL scale. Results for static and CAT CKD-QOL forms were similar. SF-12 Physical and KDQOL-36 Symptoms scores worsened with increasing comorbid condition counts. CONCLUSIONS: Overall, compared with the KDQOL-36, the new approach to summarizing CKD-specific QOL impact performed better across multiple tests of validity. CAT surveys were more efficient than static surveys.
引用
- Ware JE, Richardson MM, Meyer KB, et al. Improving CKD-Specific Patient-Reported Measures of Health-Related Quality of Life. J Am Soc Nephrol. 2019. PMID: 30898870. doi:10.1681/ASN.2018080814
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。